Annovis Stockholders Approve Doubling Authorized Shares to 140 Million
ANVS sits 30% above its 52-week low of $0.93.
Summary
Annovis stockholders approved doubling authorized common stock from 70 million to 140 million shares, and the amendment was filed in Delaware on November 4. No shares were issued — this is authorization only, though it clears the way for future equity raises.
Key Events · Corporate Governance and Compliance · ANVS
-
Authorized Shares Doubled to 140 Million
Stockholders approved increasing authorized common stock from 70,000,000 to 140,000,000 shares; the Charter Amendment was filed with the Delaware Secretary of State on November 4, 2026.
-
Vote Passed With 85.61% Support
24,084,197 votes for versus 4,047,192 against (14.39%), with 28,301,063 shares, or 66.31% of outstanding stock, represented at the November 3 Special Meeting.
-
Equity Plan Amendment Ratified
Stockholders ratified the amendment to the 2019 Equity Incentive Plan increasing shares authorized under the Option Plan, with 12,205,047 votes for (83.76%) and 2,203,711 against.
-
No Shares Issued Yet
The filing authorizes up to 140,000,000 common shares; it contains no transaction data, so no shares were sold and no proceeds were received.
Analysis · ANVS · Life Sciences
The authorized-share increase is now effective, giving Annovis room to issue equity it will likely need: the company carries a going-concern warning and reported $18.7 million in cash at Q2. This is permission to issue shares, not an issuance — no shares were sold in this filing. But the combination of a doubled share authorization and an NYSE notice that the company fails the Section 802.01B market-cap listing standard points to further dilution ahead as management works to stay funded and listed.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ANVS was trading at $1.21 on NYSE in the Life Sciences sector, with a market capitalization of approximately $51.6M. The 52-week trading range was $0.93 to $5.50. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.